In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine (original) (raw)

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

Cancer Immunology, Immunotherapy, 2011

Effect of Fludarabine on Leukocyte Functions

Chemotherapy, 2004

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

Claire Dearden

Cancer, 2010

View PDFchevron_right

The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models

Aaron Polliack

Bone Marrow Transplantation, 2000

View PDFchevron_right

Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia

Alex Sandoval

Blood, 1998

View PDFchevron_right

Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients

Melisa Stricherz

Biology of Blood and Marrow Transplantation, 2017

View PDFchevron_right

Fludarabine in chronic leukaemia

Alan Astrow

The Lancet, 1996

View PDFchevron_right

Efficacious but insidious: A retrospective analysis of fludarabine-induced myelotoxicity using long-term culture–initiating cells in 100 follicular lymphoma patients

Tomáš Pavlík

Experimental Hematology, 2009

View PDFchevron_right

Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses

Nicole Blijlevens

Biology of Blood and Marrow Transplantation, 2016

View PDFchevron_right

Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia

Salman Adil

JPMA. The Journal of the Pakistan Medical Association, 2003

View PDFchevron_right

Identifying an Optimal Fludarabine Exposure for Improved Outcomes after CD19 CAR T cell therapy for Aggressive B-NHL

Stephen Schuster

Blood Advances, 2023

View PDFchevron_right

Fludarabine-Induced Apoptosis in CD19+?/CD5+ B-CLL Cells is a Direct and Nurse-Like-Cell Independent Effect

Jordi Sierra

Leukemia & Lymphoma, 2004

View PDFchevron_right

Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias

Roberta Demichelis-gómez

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 2015

View PDFchevron_right

Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration

Giuseppe G M Leone, Dimitar Efremov

Annals of Hematology, 2008

View PDFchevron_right

Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes

Joseph O Moore

Leukemia, 2001

View PDFchevron_right

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes

M. Bierings

Blood Advances, 2019

View PDFchevron_right

In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia

Jose Manuel Montoya Gil

Blood, 1999

View PDFchevron_right

Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

Marco Gobbi

British Journal of Haematology, 2007

View PDFchevron_right

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

Joachim Schultze

Blood, 2005

View PDFchevron_right

Effect of fludarabine and arabinosylcytosine on multidrug resistant cells

Anna Candoni, Mariagrazia Michieli

Haematologica

View PDFchevron_right

Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia

Dolors Colomer

Blood, 2003

View PDFchevron_right

Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation

Janel Boyle

Pharmaceutics

View PDFchevron_right

T-cell large granular lymphocytic leukemia: Treatment experience with fludarabine

Juliana Pereira

2012

View PDFchevron_right

The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia

Romina Gamberale

Haematologica, 2006

View PDFchevron_right

Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC–MS/MS

Janel Boyle

Journal of Pharmaceutical and Biomedical Analysis, 2013

View PDFchevron_right

Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

Mohamad Hussein

Journal of Clinical Oncology, 2007

View PDFchevron_right

The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia

Richard Broekhuizen

International Journal of Oncology, 2004

View PDFchevron_right

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning

Janel Boyle

Translational Research, 2016

View PDFchevron_right

Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells

Paula Fernández Calotti

Haematologica, 2012

View PDFchevron_right

In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine (original) (raw)

Related papers